• Cordis won FDA clearance for its SELUTION SLR drug-eluting balloon to treat coronary in-stent restenosis in the US.
• Product is the first sirolimus drug-eluting balloon cleared in the US, supporting a push into the coronary drug-coated balloon market.
• SELUTION4ISR trial of more than 400 patients met its 12-month non-inferiority endpoint; target lesion failure was 15.2% versus 13.5% standard care.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cordis Corporation published the original content used to generate this news brief on September 21, 2026, and is solely responsible for the information contained therein.